Drugs / Escin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04322344 | Mar → Jun 2020 | Coronaviridae infectious disease | University of Catanzaro | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07304882 | Nov 2023 → Jan 2025 | impacted teeth, multiple | University of Science and Technology, Yemen | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02346058 | Oct 2013 → Jun 2014 | chronic venous insufficiency, thrombophlebitis, varicose disease | Ten Sun Pharma Company Limited | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07244029 | Jan → Jul 2026 overdue | — | Oman Medical Speciality Board | Recruiting | No outcome recorded |
| — | NCT06363513 | Apr → May 2024 | rectal disorder | Chiang Mai University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06748014 Comparator | Dec 2024 → Jul 2025 overdue | hemorrhoid | Chiang Mai University | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Escin | “Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.” NCT02346058 ↗ |
| Known as | Aescin | “Each tablet contains 20 mg of purified Aescin derived from Aesculus hippocastanum.” NCT07244029 ↗ |
| Action | Inhibit | “inhibiting the release of inflammatory mediators such as histamine and prostaglandins” NCT07244029 ↗ |
| Route | Topical | “Approx. 3-5 cm Gel was applied topically on skin.twice daily.” NCT02346058 ↗ |